DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2+mBC

被引：0

作者：

Andre, Fabrice

Hamilton, Erika P.

Loi, Sherene

Anders, Carey K.

Schmid, Peter

Stroyakovskiy, Daniil

Villanueva, Rafael

Pedrini, Jose Luiz

Doval, Dinesh Chandra

Zurawski, Bogdan

Chen, Shin-Cheh

Boston, Sarice Renee

Konpa, Adam

Pierotti, Barbara

Fabbri, Giulia

Jhaveri, Komal L.

机构：

[1] Univ Paris Saclay, Gustave Roussy, Villejuif, France

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Peter MacCallum Canc Ctr, Melbourne, Australia

[4] Duke Canc Inst, Durham, NC USA

[5] Queen Mary Univ London, Barts Canc Inst, London, England

[6] Moscow City Oncol Hosp 62, Moscow, Russia

[7] ICO Hosp, Barcelona, Spain

[8] Nossa Senhora Conceicao Hosp, Porto Alegre, Brazil

[9] Rajiv Gandhi Canc Inst & Res Ctr, New Delhi, India

[10] F Lukaszczyk Oncol Ctr, Bydogoszcz, Poland

[11] Linkou Chang Gung Mem Hosp, Dept Gen Surg & Breast Surg, Taoyuan, Taiwan

[12] AstraZeneca, Gaithersburg, MD USA

[13] AstraZeneca, Warsaw, Mazowieckie, Poland

[14] AstraZeneca, Boston, MA USA

[15] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1009

引用

页数：1

共 50 条

[31] Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
Dieras, Veronique
Deluche, Elise
Lusque, Amelie
Pistilli, Barbara
Bachelot, Thomas
Pierga, Jean-Yves
Viret, Frederic
Levy, Christelle
Salabert, Laura
Le Du, Fanny
Dalenc, Florence
Jouannaud, Christelle
Venat-Bouvet, Laurence
Jacquin, Jean-Philippe
Durando, Xavier
Petit, Thierry
Oukhatar, Celine Mahier -Ait
Filleron, Thomas
Mosele, Maria Fernanda
Lacroix-Triki, Magali
Ducoulombier, Agnes
Andre, Fabrice
CANCER RESEARCH, 2022, 82 (04)
[32] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
Meric-Bernstam, Funda
Makker, Vicky
Oaknin, Ana
Oh, Do-Youn
Banerjee, Susana N.
Martin, Antonio Gonzalez
Jung, Kyung Hae
Lugowska, Iwona A.
Manso, Luis
Manzano, Aranzazu
Melichar, Bohuslav
Siena, Salvatore
Stroyakovskiy, Daniil
Anoka, Chiedozie
Ma, Yan
Puvvada, Soham D.
Lee, Jung-Yun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[33] A meta-analysis analyzing the efficacy of trastuzumab-deruxtecan (T-DXd) on central nervous system (CNS) disease in patients with metastatic breast cancer (mBC)
Kumar, Prashanth Ashok
Sandhu, Michael
Sravanthi, Metlapalli Venkata
Desai, Devashish
Kumar, Vishnu Charan Suresh
Benjamin, Sam
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[34] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)
Jhaveri, Komal
Hamilton, Erika
Loi, Sherene
Schmid, Peter
Darilay, Annie
Gao, Chen
Patel, Gargi
Wrona, Magdalena
Andre, Fabrice
CANCER RESEARCH, 2021, 81 (04)
[35] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04
Modi, Shanu
Niikura, Naoki
Yamashita, Toshinari
Jacot, William
Sohn, Joohyuk
Tokunaga, Eriko
Vidal, Maria Jesus
Park, Yeon Hee
Lee, Keun Seok
Chae, Yeesoo
Ueno, Naoto T.
Prat, Aleix
Suto, Fumitaka
Kuwahara, Yusuke
McEwen, Robert
Feng, Wenqin
Goto, Hiroki
Orbegoso, Cecilia
Cameron, David A.
Tsurutani, Junji
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
Tolaney, S. M.
Barroso-Sousa, R.
Jiang, Z.
Park, Y. H.
Rimawi, M.
Manich, C. Saura
Schneeweiss, A.
Toi, M.
Yu, T.
Shetty, J.
Herbolsheimer, P.
Loibl, S.
ANNALS OF ONCOLOGY, 2021, 32 : S507 - S508
[37] A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
Cavalcante, L.
Siu, L. L.
Toso, J.
Mires, D.
Shiga, R.
Maruca, J.
Ayele, G.
Vuppala, P. Kumar
Cheng, Y.
Huang, L.
Connolly, J. E.
Ishimoto, Y.
Sue, M.
Bedard, P. L.
ANNALS OF ONCOLOGY, 2023, 34 : S333 - S333
[38] Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
Tolaney, Sara M.
Barroso-Sousa, Romualdo
Jiang, Zefei
Park, Yeon Hee
Rimawi, Mothaffar
Saura, Cristina
Schneeweiss, Andreas
Toi, Masakazu
Yu, Tinghui
Shetty, Jagdish
Herbolsheimer, Pia
Loibl, Sibylle
CANCER RESEARCH, 2022, 82 (04)
[39] Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd).
Alder, Laura
Trapani, Dario
Van Swearingen, Amanda
Khasraw, Mustafa
Anders, Carey
Lin, Nancy
Sammons, Sarah
CANCER RESEARCH, 2022, 82 (12)
[40] FEASIBILITY ASSESSMENT OF AN INDIRECT TREATMENT COMPARISON (ITC) OF SACITUZUMAB GOVITECAN (SG) VS TRASTUZUMAB DERUXTECAN (T-DXD) IN HR+/HER2-METASTATIC BREAST CANCER (MBC)
Shah, A.
Thaliffdeen, R.
Proudman, D.
Verret, W.
Sjekloca, N.
Campone, M.
VALUE IN HEALTH, 2023, 26 (12) : S545 - S545

← 1 2 3 4 5 →